(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The most effective method to Safeguard Your Teeth from Acidic Food varieties and Beverages - 2Bahrain cracks down on dissent as war grinds on
- 3Former Israeli judge does not expect Netanyahu to be pardoned
- 4Israeli archaeologists launch project to trace origins of ancient pottery
- 5Scientists sent a menstrual cup to space. This is how it went
- The Fate of Rest: Patterns in Shrewd Beds
- Top 15 Style Creators Changing the Business
- Hamas propaganda expert explains Israel's internal conflicts influenced Hamas's Oct. 7 assault
- The Best Design Bloggers for Style Motivation
- The cheap health insurance promoted by Trump officials has this catch
- Dark matter may be made of pieces of giant, exotic objects — and astronomers think they know how to look for them
- NASA study shows how satellite 'light pollution' hinders space telescopes
- The most effective method to Make a Dazzling Site in 5 Basic Advances
- Voting begins in Uganda’s presidential election during internet shutdown and polling station delays
